---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-010486"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:49:01.561003+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Syndax reports preliminary 2025 Revuforj $125M, Niktimvo $152M net rev, cash $394M

## Summary
- Revuforj preliminary net revenue $44M (Q4) and $125M (FY), up 38% QoQ.
- Niktimvo preliminary net revenue $56M (Q4) and $152M (FY); Syndax's 50% profit share expected ~25-30% of net rev.
- Cash, equivalents and marketable securities ~$394M at year-end 2025 (unaudited).
- 2026 R&D + SG&A expense guidance ~$400M (excl. $50M non-cash stock comp); company funded to profitability.
- Key 2026 milestones: complete IPF trial enrollment, advance frontline Phase 3 revumenib trials, initiate MF proof-of-principle.

## SEC filing metadata
- accession: 0001193125-26-010486
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000119312526010486/0001193125-26-010486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000119312526010486/sndx-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-010486
- JSON: https://secwatch.observer/filing/0001193125-26-010486.json
- Plain text: https://secwatch.observer/filing/0001193125-26-010486.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.